Medicare Rx "Non-Interference" Provision Is Bipartisan Target, Former CMS Official Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Statutory language prohibiting HHS from negotiating prices with drug manufacturers will likely be repealed in the next two years regardless of the presidential election's outcome, Patton Boggs partner Kathleen Means says.